Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

Arthritis and Rheumatism

Volumn 48, Issue 4, 2003, Pages 927-934

  Fleischmann, Roy M ^a   Schechtman, Joy ^b   Bennett, Ralph ^c   Handel, Malcolm L ^d   Burmester, Gerd Rudiger ^e   Tesser, John ^f   Modafferi, Dennis ^g   Poulakos, Jennifer ^g   Sun, Gordon ^g  

^a St Paul University Hospital   (United States)

^b Sun Valley Arthritis Center   (United States)

^c Arizona Arthr/Rheumatology Assoc   (United States)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Phoenix Center for Clinical Research   (United States)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 0037389680     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10870     Document Type: Article

References (35)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:59-73.
3. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
4. Bensen WG, Bensen W, Adachi JD. Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol 1997;24:1023-7.
5. Fries JF, Williams CA, Morfeld D, Sibley J. Reduction in long term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
6. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventative strategy. Ann Intern Med 1999;131:768-74.
7. Jackson CG, Williams HJ. Disease-modifying antirheumatic drugs: using their clinical pharmacological effects as a guide to their selection. Drugs 1998;56:337-44.
8. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
9. Schiff MH, Whelton A. Renal toxicity associated with disease modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000;30:196-208.
10. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
11. Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997;159:3604-12.
12. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1α/β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNFα blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
13. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
14. Rooney M, Symons JA, Duff GW. Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990;10:217-9.
15. McDonnell J, Hoerrner LA, Lark MW, Harper C, Dey T, Lobner J, et al. Recombinant human interleukin-1β-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 1992;35:799-805.
16. Van Beuningen HM, Arntz OJ, van den Berg WB. In vivo effects of interleukin-1 on articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum 1991;34:606-15.
17. Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor a, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
18. Xu LX, Kukita T, Nakano Y, Yu H, Hotokebuchi T, Kuratani T, et al. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors. Lab Invest 1996;75:677-87.
19. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
20. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
21. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156:3558-62.
22. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS Jr, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 1996;93:402-6.
23. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo FA, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900.
24. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
25. Cohen S, Hurd E, Cush JJ, Schiff MH, Weinblatt ME, Moreland LW, et al. Treatment of interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1999;42 Suppl 9:S273.
26. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. WHO Adverse Drug Reaction Terminology (WHO-ART). Uppsala, Sweden: Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Monitoring); 1997.
29. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
30. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
31. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
32. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
33. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
34. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. Infections in rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl 9:S268.
35. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.